We have a comprehensive and experienced leadership team who have come together under one organization to achieve our mission.
Johnson is a successful pharmaceutical executive who has had extensive leadership experience in both scientific and business management. As Chairman and CEO of Ribapharm, he launched the second largest biotech IPO in U.S. history. Prior to Ribapharm, he served as the Head of Worldwide Research and Development for ICN Pharmaceuticals and also as the Senior Director of Antiviral Therapy at Schering-Plough. Johnson has contributed more than 250 scientific publications and editorials/reviews/chapters in peer-reviewed scientific journals and has edited two books. He was a Director of the Board of Chelsea Therapeutics (CHTP), serving as the Chair of the Audit and Finance Committee and the Corporate Governance Committee in addition to a number of other public and privately-owned companies. Johnson is currently serving on the Board of various private companies including Avalon Biomedical Management Limited, Aiviva Corporation, C- MER D&J Technology Limited, RainsOptics Limited, and Hong Kong X-tech Startup platform (general partner and mentor). He is an Executive Board Member of the charity Project Vision, an honorary professor/adjunct professor of the University of Hong Kong and Hong Kong Polytechnic University, and a member of the Advisory Board of the School of Biomedical Sciences of the Chinese University of Hong Kong. Johnson received his medical degree (MBBS) and medical doctorate degree (MD) from the University of Hong Kong and is a Fellow of the Royal College of Physicians. Johnson has served as the Chairman of the Board of Athenex since its inception and assumed the role of CEO in mid-2011.
Jeff has held multiple senior management positions in the pharmaceutical industry over the last 46 years. Jeff was the Founder, Chairman and CEO of Sagent Pharmaceuticals which had a market cap of $1.6 billion when he left the company in 2015. Prior to that, he was the COO of American Pharmaceutical Partners where he was a founder and the company was eventually sold to Fresenius for $5.5 billion. Jeff was the CEO of Faulding Pharmaceuticals, CEO and Founder of YorPharm, COO of Gensia Pharmaceuticals and he was instrumental in the sale of all of these companies to Apotex, Teva and Hospira for prices upwards of $3.5 billion. Jeff has successfully taken four companies public and all of the companies sold for significant returns for his shareholders. Mr. Yordon was an Ernst & Young Entrepreneur of the Year in 2011, was inducted into the Chicago Entrepreneur Hall of Fame in 2014, won a prestigious Innovation Award from the City of Chicago, was appointed to the Chicago Innovation Council in 2014, was appointed by Governor Rauner to the Illinois Sports Facilities Authority in 2015, has been appointed to be the Chairman of the Board of the Northern Illinois University Foundation, is the Chair of the NIU Political Science Advisory Panel and is actively involved in the NIU Athletic program.
Rudolf has had a successful career in the pharmaceutical industry with over twenty years of experience in global clinical development and operations. Before joining Athenex, he served dual roles at Schering-Plough (SP) as Vice President and Regional Head of Asia Pacific Global Clinical Operations and Vice President of Global Clinical Development, CNS.
In the clinical operations position, Rudolf successfully recruited Heads of Clinical Operations for China, South East Asia, Australia, Taiwan and South Korea and set up the infrastructure to conduct global clinical trials in Asia Pacific for Schering-Plough. As Vice President of Global Clinical Development, CNS, he was responsible for the clinical development of all SP central nervous system drugs, globally. Major achievements included developing and executing a bioequivalence registration strategy for a new formulation of Temodol, for glioblastoma, which led to a simultaneous global registration. He also designed and executed multiple global development programs. Earlier at Schering-Plough, Rudolf held various clinical operation positions with increasing responsibility. He held similar positions at Chiron Corporation and at Smith Kline Beecham. Rudolf obtained his medical degree in Hong Kong and did subsequent training in England. He is a member and Chair of the Data Monitoring and Safety Board and Protocol Review Board for the Clinical Trial Network of the National Institute on Drug Abuse of the National Institute of Health in the USA (NIH). He is also a member of several advisory panels and grant review panels for NIH.
Simon has a long career in drug development including recent leadership roles as President and CEO of Cellectar Biosciences, President and CEO of Chelsea Therapeutics, Vice President of Oncology Pharma Business at Hoffmann-LaRoche, Life Cycle Leader and Global Project Leader of Pegasys/IFN and Head of Hepatitis Franchise at Hoffmann-LaRoche; and Vice President and Head of Drug Development in Shearwater Corporation. Formerly, he was a faculty in the Department of Pharmacology in College of Medicine in the University of Saskatchewan, where he obtained his PhD in Pharmacology. During his longstanding career in pharmaceutical development, Simon has previously led the late stage development and commercial launch of multiple proprietary pharmaceutical products. In addition to his PhD in Pharmacology, Simon obtained a Master of Science in Toxicology from Concordia University, a Bachelor of Science in Environmental Studies from the University of Waterloo, and completed the Roche-sponsored Pharmaceutical Executive Management Program at Columbia Business School.
Randoll leads corporate finance, accounting and IR matters for the Company. Randoll joined Athenex in 2017 after more than ten years in the investment banking industry. Randoll was previously with Credit Suisse’s Investment Banking and Capital Markets division, advising companies and their senior management on capital markets, mergers and acquisitions, and other financing and strategic transactions. While at Credit Suisse, Randoll led the execution of the initial public offering of Athenex. Randoll graduated with a B.S. in Chemical Engineering from University of California at Berkeley, and a M.S. in Operations Research from Columbia University.
Teresa oversees all legal matters of the Company worldwide and serves as Corporate Secretary to the Board of Directors. She also leads administration and government relations for U.S. operations and works closely with the Company’s senior management team across the globe. Prior to joining Athenex in 2015, she was a partner at Harris Beach PLLC, a nationally recognized law firm, where she successfully represented and advised business clients, including Fortune 500 companies, on complex and diverse matters. Teresa was a finalist for the 2019 ATHENA Leadership Award, and has been designated as Business First’s “Power 100 Women,” “Power 125 Women” and “Legal Elite.” While in private law practice, Teresa was consistently recognized by peer journals as a “Super Lawyer.” She serves on the Boards of Directors of BirchBioMed Inc., a clinical stage biomedical company, the Western New York Women’s Foundation, and the University at Buffalo Law Alumni Association, as well as the Advisory Boards of Varia Ventures and UB’s Buffalo Institute for Genomics & Data Analytics. Teresa received her law degree (JD) from University at Buffalo School of Law, and a Bachelor of Science in Business Administration from Bowling Green State University.
Tim began his Oncology career with Bristol-Myers Squibb where he helped launch Taxol as an oncology sales professional. He held a variety of roles of increasing responsibility including Senior Director, Payer Marketing and Senior Director, Marketing. He joined Lilly Oncology in 2000. Among the roles Tim held at Lilly were West Area Sales Director and Growth Hormone Business Unit Leader. Tim eventually became the Vice President of the North America Oncology Business Unit at Lilly Oncology. In this role Tim lead the successful launch of Alimta and the co-sponsorship of the ImClone acquisition, at the time, the largest acquisition in the history of Lilly. Tim then moved to Europe and became the VP of International Oncology at Lilly. In this role he oversaw all Oncology operations in Europe, Japan, and Australia. He led the successful launches of Cyramza in Europe and Japan. Tim then became the VP of Thoracic Product Development and Business Development. In this role he led the successful FDA approval of Portraza as well as overseeing all business development opportunities. Tim eventually became the VP and COO for Lilly Oncology where he led the overall strategic direction of the oncology business unit.
Tim joined Athenex in July of 2018 as SVP of Global Oncology. In this role he will lead the global launch efforts of oral paclitaxel and the rest of the innovative oncology pipeline.
Wing-Kai’s roles have included Director, National Center of Excellence for Clinical Trial and Research at the National University Hospital, Taiwan, and Medical Director in Roche Asia/Pacific and in that capacity, participated in the clinical development of a number of anti-cancer drugs such as: Rituxan, Herceptin and Xeloda, to name a few. Wing-Kai is a medical graduate of the University of New South Wales, Sydney, Australia and a Fellow of the Royal Australian College of Physicians. He is also a member of American Society of Clinical Oncology. Wing-Kai has authored many publications in clinical oncology over the course of his distinguished career.
Joe brings over 25 years of experience to Athenex as one of the industry’s top experts on intravenous (IV) drug delivery technologies. Prior to joining Athenex, he served as the vice president of Marketing and Business Development at Sagent Pharmaceuticals. He started his career as global engineer with DePuy Synthes, a Johnson & Johnson company, and had worked for Baxter Healthcare for 12 years. Joe has a Bachelor of Science degree in engineering from Michigan State University, and a Masters of Business Administration from Kellogg School of Management, Northwestern University.
Dan brings to Athenex with over 25 years of medicine, healthcare investment as well as leadership and business experience. Prior to joining Athenex, Dan was the Chief Investment Officer of the RS Value franchise focused on domestic equity strategies. Dan was on the executive team of RS Investment Management (RSIM) that led the sale of RSIM to Victory Capital in 2016. Prior to joining RSIM in 2009, he was an analyst at Farallon Capital Management covering biotech, medical device, pharma, and healthcare services globally. Previously, he was a senior associate at a venture capital firm, Brilleon Capital and the co-founder and CFO of Sapient Medical Group. Dan’s 25+ years of business and investment experience is preceded by a distinguished career in medicine. He was a post-doctoral research and clinical fellow in cardiology at the University of California, San Francisco and the Gladstone Cardiovascular Research Institute. He was board certified in internal medicine and a Chief Medical Resident at Mount Sinai Hospital in New York. Dan holds a BA in Chemistry from Cornell University and an MD from Cornell University Medical College.
David brings to Athenex significant scientific and managerial expertise in the field of translational pharmacology and clinical research. Prior to joining Athenex, David held leadership positions at Merck Research Laboratories and Schering-Plough Research Institute in the Department of Experimental Medicine. During his 30 years in the industry, David has made significant contributions to the successful development and registration of numerous compounds in the areas of Oncology/Immuno-Oncology, Cardiovascular Disease, and Hepatology. His expertise covers the full spectrum of therapeutic modalities including small molecules, liposomal encapsulated compounds, targeted cytotoxic conjugates, cytokines, monoclonal antibodies and gene therapies. At Schering-Plough KK (Tokyo), David was a senior executive in clinical research streamlining the research culture within the organization, resulting in numerous new drug approvals for the Japanese market.
David received his medical degree from the College of Medicine of the University of Saskatchewan. Subsequently he trained in internal medicine at the Mayo Clinic, Rochester and in Endocrinology and Metabolism at the University of Toronto and the University of California, San Diego. David is board certified in Internal Medicine and Endocrinology and Metabolism and is a Fellow of the Royal College of Physicians of Canada.
Doug has over 20 years of experience in drug development, regulatory affairs and pharmaceutical risk management. He has been involved in successful approvals of treatments for addiction (including nicotine replacement and buprenorphine for opioid dependence), opioid analgesics, and IV Temodar for glioblastoma. His work has included international drug regulatory issues and strategy and development of risk management plans for post marketing drug safety. Doug holds a Doctor of Medicine (MD) degree from Columbia University and a Bachelor of Arts degree in Chemistry from Vassar College.
William has served as President of Polymed Therapeutics since 1995 and Chairman of Chongqing Taihao Pharmaceutical since 2012. William specializes in the development, manufacturing, global sale and marketing of various complex Active Pharmaceutical Ingredients (“API”), especially the injectable Oncology APIs. William was the CEO of the Fibrocell Science (NYSE: FCSC) companies in Asia from 2010 to 2013. He introduced the first US FDA approved cell therapeutics product, LaViv, to the Asia market. William has been responsible for the building of numerous cGMP facilities in China and has extensive experience in dealing with the Food and Drug Administration in both China and the United States.
William received his PhD in Nanotechnology from Rice University where he worked extensively with Dr. Richard Smalley, the late Nobel Prize Scholar. William also has a Masters degrees in Chemical Engineering and Applied Mathematics from Rice University.
Christina brings a wealth of experience, with over 23 years in the healthcare and pharmaceutical space, including experience clinical operations, drug licensing, business development and strategic planning.
Prior to joining Athenex, Christina was a co-founder of Choice Pharma, a full-service CRO in Asia, and was instrumental in growing the business and successfully merging Choice Pharma with Clinipace Worldwide, a global CRO, in 2014, whereupon she became Executive Vice President and Board member of Asia Pacific. She has also held various positions of leadership and increasing responsibility in Oneness Biotech Co., Ltd (Taiwan:4743), GlaxoSmithKline Biologicals, Merck Sharpe & Dohme, Bayer Healthcare and Schering-Plough.
Christina is actively supporting corporate development efforts in the Asia Pacific region, focusing on partnerships and expansion opportunities, with the goal of driving Athenex’s further growth in Asia Pacific consistent with global strategy.
Carlos has had a long and successful career in the pharmaceutical industry, with over 30 years of experience in Global Clinical Operations. Before joining Athenex, he was Chief Medical Officer – South Region for CIDAL, Regional Director for Clinical Operations Latin America and Far East for Schering-Plough Research Institute (S-P), and Sr. Director Clinical Operations Latin America for Merck Sharp and Dohme (MSD). Carlos’ contributions include executing a bioequivalence trial in Argentina and Australia, which led to the global registration of a new formulation of Temodal for glioblastoma; developing the Schering Plough Global Data Management Center in Argentina; and most recently, executing the Phase 3 trial of Athenex’s oral paclitaxel and encequidar in betastatic breast cancer in Latin America.
Carlos received his M.D. from the University of Buenos Aires, School of Medicine, Argentina, and has a degree in Marketing and Pharmaceutical Business from the Universidad Abierta Interamericana in Buenos Aires, Argentina.